Intraocular Drug Delivery THAT LASTS
The first and only controlled release drug delivery platform for all cataract surgeons
HOW IT WORKS
The SpyGlass Pharma™ Drug Delivery Platform is implanted with the SpyGlass IOL into the capsular bag via standard cataract surgical technique
The SpyGlass Pharma™ Drug Delivery Platform has not been approved by the FDA
The SpyGlass Pharma™ Drug Delivery Platform consists of a single-piece, hydrophobic acrylic IOL and two drug eluting pads that slide over each haptic and securely attach at the haptic junction. With the drug pads securely attached, the IOL and pads are loaded into a standard IOL injector. The lens is advanced and injected through a sub 2.4 mm incision and implanted directly into the capsular bag.
The drug pads remain outside the visual axis and continuously elute directly into the aqueous humor, which carries the active drug to targeted tissues.
A VERSATILE SYSTEM
The SpyGlass Pharma™ Platform combines the heritage and performance of a single-piece IOL and the ability to secure innovative, drug-eluting pads to the haptics of the IOL prior to loading and implantation
Beyond bimatoprost, the SpyGlass Pharma™ drug-eluting pads are uniquely designed to deliver additional drugs to address multiple ophthalmic indications
The SpyGlass Pharma™ Drug Delivery Platform has not been approved by the FDA
CONSISTENT DAILY RELEASE
DESIGNED FOR CONSISTENT DAILY RELEASE
Targeting three years of bimatoprost sustained delivery for glaucoma management
The SpyGlass Pharma™ Drug Delivery Platform has not been approved by the FDA
PRECLINICAL TESTING
Compelling IOP lowering in normotensive beagles
-
3 doses compared to 0.03% topical bimatoprost
-
Normalized out the IOP reduction from cataract surgery alone
Clear indication of safety in NZW rabbits
-
No detectable systemic exposure
-
No drug related AEs even at 10x max dose up to 9 months
FIH FEASIBILITY STUDY
A prospective study outside of the US to evaluate the safety and efficacy of the sustained release bimatoprost implant with SpyGlass IOL in patients with ocular hypertension or mild to moderate open-angle glaucoma
The SpyGlass Pharma™ Drug Delivery Platform has not been approved by FDA
FIH Feasibility Study
Results at 3 Months
-
45% mean IOP reduction across all doses
-
All patients off topical IOP-lowering therapy